Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
Conference Paper
Full Text
Duke Authors
Cited Authors
- Hong, DS; Schoffski, P; Calvo, A; Sarantopoulos, J; Ochoa De Olza, M; Carvajal, RD; Prawira, A; Kyi, C; Esaki, T; Akerley, WL; De Braud, FG; Hui, R; Zhang, T; Soo, RA; Maur, M; Weickhardt, AJ; Roy Chowdhury, N; Sabatos-Peyton, C; Kwak, EL; Tan, DS-W
Published Date
- May 20, 2018
Published In
Volume / Issue
- 36 / 15_suppl
Start / End Page
- 3012 - 3012
Published By
Electronic International Standard Serial Number (EISSN)
- 1527-7755
International Standard Serial Number (ISSN)
- 0732-183X
Digital Object Identifier (DOI)
- 10.1200/jco.2018.36.15_suppl.3012